Trim MS to 75-85% benchmark weight; Underweight justified at 3.21x P/B (97th percentile) with $210 stop
Underweight MS justified by peak valuation (3.21x P/B, 97th percentile), asymmetric macro headwinds (30-year yields at 19-year highs, 85% no-cut probability, funding costs 4.65-5.20%), and unfavorable risk/reward (5-7% upside to $226-232 vs 10-14% downside to $206/$185.89). However, structural franchise strength (18% ROE, $7T+ client assets, 41% WM operating margins, $12B capital return capacity, flight-to-quality in stress scenarios with 70% bank-failure probability) caps downside and prevents escalation to Sell. The 8/14 modest Underweight (+0.9% alpha) and 8/13 lesson on rangebound drift for high-quality franchises at peak multiples justify 75-85% benchmark weight rather than true Hold. Stop at $210 (August structural lows) provides ~3.5% cushion (~1.3 ATR) versus sub-half-ATR $215.81 noise. Do not initiate new longs; require confirmed regime change via breakdown below $210 or breakout above $222.54 on volume >5M before adjusting.
| Position | Action |
|---|---|
| Current positioning at or above benchmark weight | Trim MS position to 75-85% of benchmark weight (~20-25% reduction) |
Morgan Stanley's 18% ROE and strategic transformation into a wealth-and-asset-management franchise with recurring fee-based revenue justify its premium P/B valuation and make the "cyclicality" and "expensive" bear arguments obsolete; combined with coiled technical momentum and multiple secular growth catalysts, MS offers a structurally superior risk/reward at current levels.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $216.57 | bullish |
| 50 SMA | $215.81 | bullish |
| 200 SMA | $185.89 | bullish |
| RSI (14) | 53.60 | neutral |
| MACD Line | +$0.97 | bullish |
| MACD Signal | +$0.51 | bullish |
| MACD Histogram | +$0.45 | bullish |
| Bollinger Upper Band | $222.54 | neutral |
| Bollinger Middle Band | $214.30 | neutral |
| Bollinger Lower Band | $206.05 | bullish |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
· concedes: Higher-for-longer rates do pressure IBD and M&A pipelines on one side of the business; The bear's caution about buying near 52-week highs is understandable on the surface; Polymarket pricing 70% probability of a bank failure by year-end represents tail risk that could impact sentiment
MS is a high-quality franchise being priced for permanent perfection at peak earnings, peak multiple, and peak macro tailwinds that are already reversing—the risk/reward is 14.6% downside versus 4.1-6.7% upside, making SELL/HEDGE the appropriate action.
EV: -14.6% · concedes: MS is directionally more wealth-and-asset-management weighted than a decade ago (granted); Directional truth that WM/IM mix has de-cycled the franchise partially conceded; Bond sell-off confirmed (Nasdaq dropped 355 pts); Higher rates do boost NII (true for now); MS benefits from flight-to-quality (works in orderly market stress)
→ vs conservative: Anchoring on Q2 record results as new baseline is analytical malpractice—Q2 surge was cyclical composition from trading desk windfalls and IBD backlog that won't repeat
→ vs conservative: $7.2 billion buyback program is rearview-mirror thinking; buybacks don't matter if multiple compresses 15-20% in next 12 months
→ vs conservative: Underestimating rate risk exposure—$391 billion in long-term debt at 4.65-5.20% coupons will see funding costs compress margins as debt rolls
→ vs conservative: 'High bar set but no immediate catalyst' essentially means no view on systemic risk—professing to have no view on 70% bank failure probability is abdication, not prudence
→ vs neutral: HOLD with 'strong capital return' caveat ignores that MS is at 93rd percentile of 52-week range—that's not risk management, that's hope
→ vs neutral: HOLD with caveat 'watch the 30-year yield' admits the catalyst exists but refuses to act preemptively—a strategy that works until it doesn't, then you're catching a falling knife
→ vs neutral: Technical 'HOLD with bullish bias' framework is dangerously myopic—price coiled between $215.81 and $222.54 with bond yields backing up means path of least resistance is breakdown, not breakout
→ vs neutral: Quality compounder argument with 'await better entry point' contradicts holding full position at 93rd percentile of 52-week range
| $5.28 |
| neutral |
Support: 215.81 · 214.3 · 210.42 · 206.05 · 202.02 | Resistance: 218 · 220 · 222.54 · 226.42
MS is at a critical inflection point following a two-month rally (~$165 to $226.42 peak), an 11% pullback to $202.02, and a textbook recovery. The stock is consolidating near its 50-day SMA with momentum indicators turning neutral-to-positive (RSI 53.60, MACD crossed positive August 7), suggesting a basing pattern rather than trend exhaustion. The long-term uptrend remains firmly intact 17% above the 200 SMA at $185.89. Bollinger bands are contracting, indicating coiling for a directional breakout. Current recommendation is HOLD with bullish bias; a daily close above $222.54 (upper Bollinger band) on rising volume would trigger an upgrade to BUY with targets at $226.42 and $230.00+. Key risks include failure of 50 SMA support and potential retest of the $200 level.
Market Cap
$341.99B
Stock Price (implied)
~$217.50
52-Week Range
$141.03 – $232.25
50-Day MA
$216.58
200-Day MA
$187.44
Beta
1.21
P/E (TTM)
17.59
Forward P/E
15.96
PEG Ratio
2.06
P/B
3.21
Dividend Yield
2.11%
EPS (TTM)
$12.37
Forward EPS
$13.63
Book Value
$67.80
Q2 2026 Revenue
$19,884M
Q2 2026 Net Income
$5,581M
Q2 2026 Diluted EPS
$3.46
Q1 2026 Revenue
$19,324M
Q1 2026 Net Income
$5,567M
Q1 2026 Diluted EPS
$3.43
Q4 2025 Revenue
$16,762M
Q4 2025 Net Income
$4,397M
Q4 2025 Diluted EPS
$2.68
Q3 2025 Revenue
$17,083M
Q3 2025 Net Income
$4,610M
Q3 2025 Diluted EPS
$2.80
Q2 2025 Revenue
$15,604M
Q2 2025 Net Income
$3,539M
Q2 2025 Diluted EPS
$2.13
2025 Annual Revenue
$65.97B
2025 Annual Net Income
$16.86B
2025 Annual Diluted EPS
$10.21
2025 Pretax Income
$21.95B
2024 Annual Revenue
$57.62B
2024 Annual Net Income
$13.39B
2024 Annual Diluted EPS
$7.95
2024 Pretax Income
$17.60B
2023 Annual Revenue
$50.67B
2023 Annual Net Income
$9.09B
2023 Annual Diluted EPS
$5.18
2023 Pretax Income
$11.81B
2022 Annual Revenue
$50.21B
2022 Annual Net Income
$11.03B
2022 Annual Diluted EPS
$6.15
2022 Pretax Income
$14.09B
TTM Revenue
$77.83B
EPS Growth 2023 to 2025
+97%
Diluted Shares 2022
1.713B
Diluted Shares 2025
1.592B
Diluted Shares Q2 2026
1.569B
Profit Margin
25.90%
Operating Margin
41.57%
Return on Equity (ROE)
17.97%
Return on Assets (ROA)
1.35%
Current Ratio
2.00
Compensation/Revenue Q2 2026
~41%
Q2 2026 Total Assets
$1,675.06B
Q2 2026 Total Liabilities
$1,557.62B
Q2 2026 Total Equity
$117.44B
Q2 2026 Common Stock Equity
$106.58B
Q2 2026 Cash & Equivalents
$123.04B
Q2 2026 Total Cash & Fed Funds Sold
$289.65B
Q2 2026 Trading Securities
$265.88B
Q2 2026 Net Loans
$302.38B
Q2 2026 Long-Term Debt
$391.46B
Q2 2026 Total Debt
$422.38B
Q2 2026 Goodwill & Intangibles
$22.98B
Q2 2026 Tangible Book Value
$83.60B
Q2 2026 Retained Earnings
$122.77B
Net Debt
$299.34B
Net Interest Income Q2 2026
$2.78B
Interest Income Q2 2026
$15.90B
Interest Expense Q2 2026
$13.12B
Gain on Sale of Securities Q2 2026
$226M
Q2 2026 Operating Cash Flow
-$2.75B
Q2 2026 Free Cash Flow
-$3.57B
Q2 2026 Buybacks
$1.67B
Q2 2026 Dividends
$1.68B
TTM Buybacks
~$7.2B
TTM Dividends
~$6.8B
2025 Total Capital Return
~$12.4B
2025 Buybacks
$5.84B
2025 Dividends
$6.59B
2025 Operating Cash Flow
-$17.89B
2025 Free Cash Flow
-$20.79B
2024 Buybacks
$4.20B
2024 Dividends
$6.14B
2024 Operating Cash Flow
$1.36B
2024 Free Cash Flow
-$2.10B
2023 Buybacks
$6.18B
2023 Dividends
$5.76B
2023 Operating Cash Flow
-$33.54B
2023 Free Cash Flow
-$36.95B
Treasury Stock Q2 2025
$35.5B
Treasury Stock Q2 2026
$41.5B
LT Debt Issued Q2 2026
$43.25B
2025 LT Debt Issued
$139.17B
2024 LT Debt Issued
$108.37B
2023 LT Debt Issued
$78.42B
2022 LT Debt Issued
$72.46B
Strengths
Concerns
Morgan Stanley is executing at its highest level in history, delivering record Q2 2026 revenue of $19.88B (+27.4% YoY) and net income of $5.58B, with trailing-twelve-month revenue reaching an all-time high of $77.83B. The firm maintains best-in-class ROE of 17.97% and operating margin of 41.6%, driven by its dominant Wealth Management segment which now contributes the majority of profits. Capital returns remain robust with $12.4B returned to shareholders in 2025 through a combination of buybacks and dividends, while diluted share count has declined 8.4% since 2022. Despite the overwhelmingly positive fundamental story, the stock trades near 52-week highs at a premium valuation (3.2x P/B, 17.6x P/E, 2.06x PEG), and the recommendation is HOLD pending a pullback to the 200-day moving average (~187) for better risk/reward on new positions.
Macro: Higher-for-longer rate backdrop with 85% probability of zero Fed rate cuts in 2026 and 52% probability of no hikes. 30-year Treasury yield at 19-year high amid bond sell-off slamming equities. Polymarket recession odds at 8% for US (declining), 12% UK, 31% Japan. Bank failure odds at 70% for US by year-end. Soft landing consensus supports wealth management AUM; AI capex super-cycle and crypto institutionalization are cross-cutting secular themes favoring MS.